Log in

Relevant bibliographies by topics / Optimal Cytoreduction / Journal articles

To see the other types of publications on this topic, follow the link: Optimal Cytoreduction.

Journal articles on the topic 'Optimal Cytoreduction'

Author: Grafiati

Published: 9 March 2023

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Optimal Cytoreduction.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Memarzadeh, S., S. B. Lee, J. S. Berek, and R. Farias-Eisner. "CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer." International Journal of Gynecologic Cancer 13, no. 2 (2003): 120–24. http://dx.doi.org/10.1136/ijgc-00009577-200303000-00003.

Full text

Abstract:

The utility of preoperative CA125 to predict optimal primary tumor cytoreduction in patients with advanced (stages IIIC and IV) epithelial ovarian cancer is controversial. In this paper, we retrospectively review patients with stage IIIC and IV epithelial ovarian cancer who underwent primary cytoreductive surgery from 1989 to 2001. Ninety-nine patients were identified and included in the analysis. All patients had preoperative CA125 levels measured. Operative and pathology reports were reviewed. Optimal cytoreduction was defined as largest volume of residual disease < 1 cm in maximal dimens

APA, Harvard, Vancouver, ISO, and other styles

2

Lūža, Tomas, Agnė Ožalinskaitė, and Vilius Rudaitis. "The rate and role of diaphragmatic peritonectomy in optimal cytoreduction in patients with advanced stage ovarian cancer: a prospective study of 100 patients." Acta medica Lituanica 21, no. 1 (2014): 1–7. http://dx.doi.org/10.6001/actamedica.v21i1.2882.

Full text

Abstract:

Background. Diaphragmatic peritoneal metastasis by advanced epithelial ovarian cancer is a very common holdback precluding optimal cytoreduction. The aim of this study was to determine the rate of diaphragmatic peritonectomy during optimal cytoreductive surgery and its role in postoperative morbidity and survival in patients with advanced ovarian cancer. Materials and methods. 100 consecutive patients with advanced epithelial ovarian cancer underwent cytoreductive surgery and were followed up prospectively (January 2009 – March 2014). Characteristics of surgery, rate of diaphragmatic periton

APA, Harvard, Vancouver, ISO, and other styles

3

A, Camargo, Bianchi F, Habich D, and Castaño R. "The fundamental role of the exploration of the upper abdomen in ovarian cancer surgery." Obstetrics & Gynecology International Journal 12, no. 5 (2021): 337–42. http://dx.doi.org/10.15406/ogij.2021.12.00603.

Full text

Abstract:

Purpose: Several studies have shown the benefit of cytoreductive surgery in advanced disease, that is why the residual tumor has prognostic value. Our primary objective was to determine the frequency of involvement of the upper abdomen, defined as the extension of the disease above the transverse colon (diaphragm, spleen, gallbladder, stomach, hepatic parenchyma, hepatic capsule, minor omentum, hepatic ilium, pancreas). Our secondary objective was to analyze the possibilities of complete cytoreduction in these patients, their complications and results. Materials and methods: We retrospectively

APA, Harvard, Vancouver, ISO, and other styles

4

Abdullaev, A. G., М. M. Davydov, and N. A. Коzlov. "CHALLENGES IN CHOICE OF THE TREATMENT STRATEGY FOR PATIENTS WITH RECURRENT PSEUDOMYXOMA PERITONEI." Siberian journal of oncology 18, no. 3 (2019): 78–83. http://dx.doi.org/10.21294/1814-4861-2019-18-3-78-83.

Full text

Abstract:

Pseudomixoma peritonei is a rare type of peritoneal carcinomatosis accompanied by accumulation of mucus and high recurrence rate and in some cases complicated with intestinal obstruction. In the last 10–15 years, there has been observed a significant improvement in overall survival of patients with recurrent pseudomyxoma, who underwent cytoreductive surgery in combination with intraperitoneal chemotherapy. However, the frequency of recurrences of peritoneal pseudomyxoma after optimal cytoreduction can reach 80–90 % in the first 2 years.The purpose of the study was to analyze the results of com

APA, Harvard, Vancouver, ISO, and other styles

5

Turan, Taner, Tolga Tasci, Alper Karalok, et al. "Salvage Cytoreductive Surgery for Recurrent Endometrial Cancer." International Journal of Gynecologic Cancer 25, no. 9 (2015): 1623–32. http://dx.doi.org/10.1097/igc.0000000000000543.

Full text

Abstract:

ObjectiveThe aim of this study was to determine the effect of salvage cytoreductive surgery (SCS) on overall survival (OS) among patients with recurrent endometrial cancer and if there is any predictor for residual tumor status.MethodsBetween January 1993 and May 2013, data of 34 patients who had SCS for recurrent endometrial cancer were retrospectively analyzed. Overall survival was determined from SCS to last follow-up.ResultsThe surgical procedure was local excision without laparotomy in 12 patients, and optimal cytoreduction (no visible disease) was achieved in 24 of 34 patients. There wer

APA, Harvard, Vancouver, ISO, and other styles

6

Roberts, William S. "Cytoreductive Surgery in Ovarian Cancer: Why, When, and How?" Cancer Control 3, no. 2 (1996): 130–36. http://dx.doi.org/10.1177/107327489600300205.

Full text

Abstract:

Retrospective evidence supports the value of optimal cytoreductive surgery in the initial therapy of patients with advanced ovarian cancer. Specialized procedures, including radical pelvic surgery, bowel resection, and diaphragm resections, are frequently necessary to accomplish optimal cytoreduction. Cytoreduction and total gross tumor removal are possible more frequently with new surgical instruments such as the Cavitron ultrasonic surgical aspirator and argon beam laser. Pelvic and periaortic lymph node resection is an important aspect of cytoreductive surgery, and systematic removal of gro

APA, Harvard, Vancouver, ISO, and other styles

7

Abdalla Ahmed, Shimaa, Hisham Abou-Taleb, Noha Ali, and Dalia M. Badary. "Accuracy of radiologic– laparoscopic peritoneal carcinomatosis categorization in the prediction of surgical outcome." British Journal of Radiology 92, no. 1100 (2019): 20190163. http://dx.doi.org/10.1259/bjr.20190163.

Full text

Abstract:

Objective: To evaluate the agreement between multiple detector CT (MDCT) and laparoscopy in the preoperative categorization of peritoneal carcinomatosis, and to determine the impact of this categorization on the prediction of cytoreduction status. Methods: This prospective study included 80 consecutive females with primary ovarian cancer eligible for cytoreductive surgery (CRS). MDCT and diagnostic laparoscopy were performed prior to surgery for assessment of peritoneal carcinomatosis extent. Based on PCI (peritoneal cancer index) score, carcinomatosis was categorized into three groups. Catego

APA, Harvard, Vancouver, ISO, and other styles

8

Cardillo, Nicholas, Eric J. Devor, Silvana Pedra Nobre, et al. "Integrated Clinical and Genomic Models to Predict Optimal Cytoreduction in High-Grade Serous Ovarian Cancer." Cancers 14, no. 14 (2022): 3554. http://dx.doi.org/10.3390/cancers14143554.

Full text

Abstract:

Advanced high-grade serous (HGSC) ovarian cancer is treated with either primary surgery followed by chemotherapy or neoadjuvant chemotherapy followed by interval surgery. The decision to proceed with surgery primarily or after chemotherapy is based on a surgeon’s clinical assessment and prediction of an optimal outcome. Optimal and complete cytoreductive surgery are correlated with improved overall survival. This clinical assessment results in an optimal surgery approximately 70% of the time. We hypothesize that this prediction can be improved by using biological tumor data to predict optimal

APA, Harvard, Vancouver, ISO, and other styles

9

Abdallah, Reem, Hye Sook Chon, Nadim Bou Zgheib, et al. "Prediction of Optimal Cytoreductive Surgery of Serous Ovarian Cancer With Gene Expression Data." International Journal of Gynecologic Cancer 25, no. 6 (2015): 1000–1009. http://dx.doi.org/10.1097/igc.0000000000000449.

Full text

Abstract:

ObjectivesCytoreductive surgery is the cornerstone of ovarian cancer (OVCA) treatment. Detractors of initial maximal surgical effort argue that aggressive tumor biology will dictate survival, not the surgical effort. We investigated the role of biology in achieving optimal cytoreduction in serous OVCA using microarray gene expression analysis.MethodsFor the initial model, we used a gene expression signature from a microarray expression analysis of 124 women with serous OVCA, defining optimal cytoreduction as removal of all disease greater than 1 cm (with 64 women having optimal and 60 suboptim

APA, Harvard, Vancouver, ISO, and other styles

10

Arits, A. H. M. M., J. E. G. M. Stoot, A. A. M. Botterweck, F. J. M. E. Roumen, and A. C. Voogd. "Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer." International Journal of Gynecologic Cancer 18, no. 4 (2008): 621–28. http://dx.doi.org/10.1136/ijgc-00009577-200807000-00004.

Full text

Abstract:

The objective is to assess the ability of preoperative serum CA125 levels to identify patients at high risk of suboptimal cytoreductive surgery for epithelial ovarian cancer (EOC). One hundred and thirty-two women diagnosed with EOC between 1998 and 2004, who had serum CA125 levels measured preoperatively and received primary cytoreductive surgery, were retrospectively evaluated. The value of CA125 and patient and disease characteristics to predict suboptimal cytoreduction were determined, and a prognostic scoring system, based on statistically significant variables, was created. Optimal cytor

APA, Harvard, Vancouver, ISO, and other styles

11

Huda, Sheikh Farhana, Fawzia Hossain, Muhammad Jasim Uddin, Kaniz Farhana, and Shah Md Mahfuzur Rahman. "Evaluation of preoperative predictors of optimal cytoreductive surgery in women with epithelial ovarian cancer." Bangladesh Medical Research Council Bulletin 47, no. 3 (2022): 280–88. https://doi.org/10.3329/bmrcb.v47i3.59993.

Full text

Abstract:

Background: Globally, among gynaecologic cancers, ovarian cancer represents higher morbidity and mortality. Approximately, 90% of ovarian cancer are epithelial in origin. Primary cytoreductive surgery followed by chemotherapy is the cornerstone of treatment for epithelial ovarian cancer. Suboptimal cytoreduction may result in surgical complications and delay in chemotherapy which are against survival. Therefore, it is important to predict patients who are unlikely to achieve optimum cytoreduction.Objectives: To evaluate the preoperative clinical, laboratory and radiographic parameters to predi

APA, Harvard, Vancouver, ISO, and other styles

12

Abitbol, Jeremie, Walter Gotlieb, Ziggy Zeng, et al. "Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy." International Journal of Gynecologic Cancer 29, no. 9 (2019): 1341–47. http://dx.doi.org/10.1136/ijgc-2019-000413.

Full text

Abstract:

IntroductionWith the rapid uptake of robotic surgery in surgical oncology, its use in the treatment of epithelial ovarian cancers is being evaluated. Complete cytoreduction represents the goal of surgery either at primary cytoreduction or after neoadjuvant chemotherapy in the setting of interval cytoreduction. In selected patients, the extent of disease would enable minimally invasive surgery. The objective of this study was to evaluate the impact of introducing robotic surgery for interval cytoreduction of selected patients with stage III–IV ovarian cancer.MethodsAll patients who underwent su

APA, Harvard, Vancouver, ISO, and other styles

13

Nam, J. H., Y. M. Kim, M. H. Jung, et al. "Primary peritoneal carcinoma: experience with cytoreductive surgery and combination chemotherapy." International Journal of Gynecologic Cancer 16, no. 1 (2006): 23–28. http://dx.doi.org/10.1136/ijgc-00009577-200601000-00004.

Full text

Abstract:

The objective of this study was to review the clinical outcome and prognosis of patients with primary peritoneal carcinoma (PPC) treated with cytoreductive surgery and combination chemotherapy. We retrospectively reviewed the charts of 27 patients with histologically confirmed PPC, treated between March 1990 and February 2004 at Asan Medical Center, South Korea. The review included demographic data, pathologic findings, treatments, and outcomes. The mean age of the 27 patients was 57.5 ± 7.2 years, and the rate of optimal cytoreduction was 70.4%. Seven patients had stage IIIB, 17 had stage III

APA, Harvard, Vancouver, ISO, and other styles

14

Ayhan, A., C. Taskiran, C. Celik, K. Yuce, and T. Kucukali. "The influence of cytoreductive surgery on survival and morbidity in stage IVB endometrial cancer." International Journal of Gynecologic Cancer 12, no. 5 (2002): 448–53. http://dx.doi.org/10.1136/ijgc-00009577-200209000-00007.

Full text

Abstract:

The purpose of this study was to detect possible survival advantages of surgical cytoreduction and different adjuvant treatment regimens for stage IVB endometrial cancer patients, and also to evaluate the prognostic importance of surgico-pathological risk factors and surgical morbidity rates.Thirty-seven FIGO stage IVB endometrial cancer patients treated at the Hacettepe University Hospital between 1977 and 1998 were included in this study. Clinical data were obtained from the private oncology files and all specimens were re-evaluated by the co-author pathologist. Optimal cytoreduction was def

APA, Harvard, Vancouver, ISO, and other styles

15

Gaba, Faiza, Oleg Blyuss, Dhivya Chandrasekaran, et al. "Prognosis Following Surgery for Recurrent Ovarian Cancer and Diagnostic Criteria Predictive of Cytoreduction Success: A Systematic Review and Meta-Analysis." Diagnostics 13, no. 22 (2023): 3484. http://dx.doi.org/10.3390/diagnostics13223484.

Full text

Abstract:

For women achieving clinical remission after the completion of initial treatment for epithelial ovarian cancer, 80% with advanced-stage disease will develop recurrence. However, the standard treatment of women with recurrent platinum-sensitive diseases remains poorly defined. Secondary (SCS), tertiary (TCS) or quaternary (QCS) cytoreduction surgery for recurrence has been suggested to be associated with increased overall survival (OS). We searched five databases for studies reporting death rate, OS, cytoreduction rates, post-operative morbidity/mortality and diagnostic models predicting comple

APA, Harvard, Vancouver, ISO, and other styles

16

Kumar, D. Suresh, S. Navin Noushad, and M. P. Viswanathan. "Pelvic lymphadenectomy as a component of interval cytoreduction for ovarian cancer: is there a benefit? A pilot study." International Journal of Research in Medical Sciences 5, no. 3 (2017): 821. http://dx.doi.org/10.18203/2320-6012.ijrms20170515.

Full text

Abstract:

Background: Management strategy in ovarian cancer includes a combination of cytoreductive surgery and chemotherapy. Interval cytoreductive surgery has been shown to be oncologically non-inferior to primary cytoreduction with the additional benefit of reduced morbidity. Lymphadenectomy as a component of cytoreductive surgery has been controversial with an unproven therapeutic benefit.Methods: Records of patients with a histological diagnosis of ovarian cancer and treated with interval cytoreduction were evaluated. Disease related, pathological and treatment data collected for analysis.Results:

APA, Harvard, Vancouver, ISO, and other styles

17

Bridges, J. E., Y. Leung, I. G. Hammond, and A. J. Mccartney. "En bloc resection of epithelial ovarian tumors with concomitant rectosigmoid colectomy: the KEMH experience." International Journal of Gynecologic Cancer 3, no. 4 (1993): 199–202. http://dx.doi.org/10.1046/j.1525-1438.1993.03040199.x.

Full text

Abstract:

Between the years 1984 and 1988, 43 patients with bulky advanced stage epithelial ovarian carcinoma underwent en bloc pelvic resection with excision of the rectosigmoid colon as part of their primary cytoreductive surgery. Optimal cytoreduction was accomplished in over 70% of cases, and all women had complete debulking of their pelvic tumor. Primary anastomosis of the bowel was feasible in all cases and only two covering colostomies were performed. There were no postoperative leaks or fistulas. The postoperative morbidity was reflected by a mean postoperative hospital stay of 16 days. Our resu

APA, Harvard, Vancouver, ISO, and other styles

18

Rybin, A. I. "The results of personificated ovarian cancer patients with peritoneal carcinomatosis treatment." Reproductive health of woman, no. 7 (November 30, 2022): 35–40. http://dx.doi.org/10.30841/2708-8731.7.2022.272470.

Full text

Abstract:

The objective: to analyse of the experience of cytoreductive surgery using and hypenermic intraperitoneal chemperfusion (HIPEC) in patients with ovarian cancer IIIC stage, as well as overall and relapse-free survival in such patients. Materials and methods. 119 patients with ovarian cancer of the IIIC stage were involved into the study from 2013 to 2020 and they were treated at the University Clinic of Odessa National Medical University. Patients were divided into two groups: the clinical control group (n=53) included persons after suboptimal cytoreduction; the patients of the main group (n=66

APA, Harvard, Vancouver, ISO, and other styles

19

Parveen, Pabina Afroz, Fawzia Hossain, Shah Mahfuzur Rahman, Rezwana Sharmin Lima, Anjuman Sultana, and Nahida Sultana. "A Predictive Score after Neoadjuvant Chemotherapy for Optimal Cytoreduction at Interval Debulking Surgery in Advanced Epithelial Ovarian Cancer." Bangladesh Medical Research Council Bulletin 48, no. 2 (2023): 154–59. http://dx.doi.org/10.3329/bmrcb.v48i2.62302.

Full text

Abstract:

Background: Ovarian cancer is the seventh most common cancer and eighth most common cause of death of female. More than 75% patients are diagnosed at Stage (III - IV) and their 5-year survival rate is (25-50%) . Primary debulking surgery (PDS) followed by adjuvant chemotherapy is the cornerstone treatment for advanced ovarian cancer. Unfortunately, primary debulking surgery is not always feasible and not associated with optimal cytoreduction. Recently, neoadjuvant chemotherapy followed by Interval Debulking Surgery (NACT- IDS) is increasingly adopted. (NACT-IDS) improves optimal cytoreduction

APA, Harvard, Vancouver, ISO, and other styles

20

Anuvi, Ratnesh, and Pendurthi Mahalakshmi. "Interval Debulking Surgery (IDS) in Advanced Ovarian Cancer – Immediate Surgical Outcomes and Optimal Cytoreduction Rate." International Journal of Science and Healthcare Research 5, no. 2 (2020): 199–204. https://doi.org/10.5281/zenodo.3931483.

Full text

Abstract:

<strong>Introduction</strong>: In Indian women, ovarian cancer is the fourth most common cancer, out of which epithelial ovarian cancers are the most common and present in advanced stage. Women with other comorbidities and those who are unlikely to achieve optimal debulking at primary surgery, benefit from neoadjuvant chemotherapy (NACT) followed by interval cytoreduction, with lesser surgical morbidity and equal survival rates as compared to primary cytoreduction. <strong>Material & methods</strong>: A 1 year retrospective study was conducted at tertiary care hospital situated in Bangalor

APA, Harvard, Vancouver, ISO, and other styles

21

Angarita, Ana Milena, Rebecca Stone, Sarah M. Temkin, Kimberly Levinson, Amanda N. Fader, and Edward J. Tanner. "The Use of “Optimal Cytoreduction” Nomenclature in Ovarian Cancer Literature: Can We Move Toward a More Optimal Classification System?" International Journal of Gynecologic Cancer 26, no. 8 (2016): 1421–27. http://dx.doi.org/10.1097/igc.0000000000000796.

Full text

Abstract:

ObjectivesThe objective of this study is to explore how cytoreductive surgical outcomes such as residual disease (RD) and use of the term “optimal cytoreduction” (OCR) have changed over time in the ovarian cancer literature.MethodsWe identified all English-language publications referring to ovarian cancer cytoreduction for a 12-year period. Publications were evaluated for how the diameter of RD was categorized and whether OCR was defined. In addition, the use of RD and OCR terminology trends over time and associations between terminology and the region of corresponding author, study type, and

APA, Harvard, Vancouver, ISO, and other styles

22

A.I., Rybin. "THE RESULTS OF PERSONIFICATED OVARIAN CANCER PATIENTS WITH PERITONEAL CARCINOMATOSIS TREATMENT." Reproductive Health of Woman, no. 7 (November 30, 2022): 35–40. https://doi.org/10.30841/2708-8731.7.2022.272470.

Full text

Abstract:

<strong>The objective:</strong> to analyse of the experience of cytoreductive surgery using and hypenermic intraperitoneal chemperfusion (HIPEC) in patients with ovarian cancer IIIC stage, as well as overall and relapse-free survival in such patients. <strong>Materials and methods.</strong> 119 patients with ovarian cancer of the IIIC stage were involved into the study from 2013 to 2020 and they were treated at the University Clinic of Odessa National Medical University. Patients were divided into two groups: the clinical control group (n=53) included persons after suboptimal cytored

APA, Harvard, Vancouver, ISO, and other styles

23

Xu, Xiaojuan, Yan Chen, Xinxin Zhang, and Yilin Wang. "Association between the quantitative characteristics of dual-energy spectral CT and cytoreduction surgery outcome in patients with advanced epithelial ovarian cancers: A prospective observational study." Medicine 103, no. 10 (2024): e37437. http://dx.doi.org/10.1097/md.0000000000037437.

Full text

Abstract:

This study aimed to explore the association between the quantitative characteristics of dual-energy spectral CT and cytoreduction surgery outcome in patients with advanced epithelial ovarian carcinoma (EOC). In this prospective observational study, patients with advanced EOC (federation of gynecology and obstetrics stage III–IV) treated in the Department of Gynecological Oncology at our Hospital between June 2021 and March 2022 were enrolled. All participants underwent dual-energy spectral computed tomography (DECT) scanning 2 weeks before cytoreductive surgery. The quantitative data included

APA, Harvard, Vancouver, ISO, and other styles

24

Wakabayashi, Mark T., Paul S. Lin, and Amy A. Hakim. "The Role of Cytoreductive/Debulking Surgery in Ovarian Cancer." Journal of the National Comprehensive Cancer Network 6, no. 8 (2008): 803–11. http://dx.doi.org/10.6004/jnccn.2008.0060.

Full text

Abstract:

Ovarian cancer is the fifth most common cause of cancer-related death among women in the United States, although the median survival of patients has been increasing over the past few decades. In patients with epithelial ovarian cancer, chemotherapy has increased survival. Platinum agents combined with taxanes have become standard treatment. Intraperitoneal chemotherapy has also increased survival. Cytoreductive surgery to optimally debulk a tumor or, ideally, remove any gross disease has also been shown to increase survival. Each 10% increase in cytoreduction correlates with a 5.5% increase in

APA, Harvard, Vancouver, ISO, and other styles

25

Kozhevnikova, O. V., R. I. Knyazev, V. S. Ananyev, et al. "Long-term results of bowel resection as a component of cytoreductive surgery for advanced ovarian cancer." Surgery and Oncology 15, no. 1 (2025): 54–61. https://doi.org/10.17650/2949-5857-2025-15-1-54-61.

Full text

Abstract:

Introduction. Ovarian cancer is one of the leading causes of death from cancer of the female reproductive system. Despite the use of modern drugs, patient survival remains unsatisfactory. In this regard, it is necessary to expand the scope of surgical interventions in this category of patients, which is impossible without performing surgery on the small or large intestine.Aim. To analyze the long-term results of cytoreductive surgery in patients with advanced ovarian cancer involving the small or large intestine in the tumor process.Materials and methods. Our retrospective study included 105 p

APA, Harvard, Vancouver, ISO, and other styles

26

Tjulandina, A. S., A. A. Rumyantsev, K. Y. Morkhov, V. M. Nechushkina, and S. A. Tjulandin. "RETROSPECTIVE ANALYSIS OF LONG-TERM SURVIVAL OUTCOMES OF PRIMARY CYTOREDUCTION AND NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH OVARIAN CANCER STAGE IIIC–IV." Malignant tumours 8, no. 3 (2018): 86–94. http://dx.doi.org/10.18027/2224-5057-2018-8-3-86-94.

Full text

Abstract:

The choice of treatment strategy in patients with stage IIIC‑IV ovarian cancer (OC) remains the subject of numerous discussions. The reason for this is the unsatisfactory results of randomized trials and the low frequency of primary complete debulking surgery in these studies. We conducted a retrospective analysis to evaluate the survival outcomes in patients with OC stage IIIC–IV (n=314) who underwent treatment between 1995 and 2017. The median progression free survival for primary surgery was 15.6 months, after interval debulking – 11.5 months (p=0.002, HR 0.61: 95 % CI 0.39–0.81). The prima

APA, Harvard, Vancouver, ISO, and other styles

27

Bandala-Jacques, Antonio, Fabiola Estrada-Rivera, David Cantu, et al. "Role of optimal cytoreduction in patients with dysgerminoma." International Journal of Gynecologic Cancer 29, no. 9 (2019): 1405–10. http://dx.doi.org/10.1136/ijgc-2019-000632.

Full text

Abstract:

BackgroundDysgerminomas are malignant ovarian germ-cell tumors that typically affect young women. Although these tumors have an excellent response to chemotherapy, surgery is an integral part of primary treatment.ObjectiveTo evaluate outcomes of initial cytoreduction in patients diagnosed with dysgerminomas.MethodsPatients who underwent primary cytoreductive surgery for ovarian dysgerminoma between January 1985 and December 2013 were identified and included in the study. A comparison was made between patients who underwent optimal versus sub-optimal cytoreduction. Descriptive, comparative stat

APA, Harvard, Vancouver, ISO, and other styles

28

Tuninetti, Valentina, Marilena Di Napoli, Eleonora Ghisoni, et al. "Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience." Cancers 12, no. 8 (2020): 2239. http://dx.doi.org/10.3390/cancers12082239.

Full text

Abstract:

Few retrospective studies have shown a benefit in selected patients affected by heavily pre-treated, platinum-resistant ovarian carcinomas (PROCs) who have undergone cytoreduction at relapse. However, the role of tertiary and quaternary cytoreductive surgery is not fully defined. Our aim was to evaluate survival and surgical morbidity and mortality after maximal cytoreduction in this setting. We evaluated all consecutive patients undergoing cytoreduction for platinum-resistance over an 8-year period (2010–2018) in two different centers. Fifty patients (median age 52.5 years, range 34–75) were

APA, Harvard, Vancouver, ISO, and other styles

29

Bacalbasa, Nicolae, Olivia Ionescu, Paris Ionescu, and Irina Balescu. "Digestive resections in advanced-stage ovarian cancer." Advances in Modern Oncology Research 2, no. 3 (2016): 132. http://dx.doi.org/10.18282/amor.v2.i3.87.

Full text

Abstract:

The standard frontline treatment for advanced-stage ovarian cancer (ASOC) consists of maximal cytoreduction surgery associated with platinum/paclitaxel-based chemotherapy. Several studies have proven that patients with no gross residual disease (RD) have better survival rates than those with optimal but visible RD (RD ≤1 cm). In order to achieve this, more radical cytoreductive procedures such as radical pelvic resection and extensive upper abdominal procedures are performed. However, some investigators have suggested that, although effective, radical surgery cannot fully compensate tumor biol

APA, Harvard, Vancouver, ISO, and other styles

30

Van Wijk, F. H., F. J. Huikeshoven, L. Abdulkadir, P. C. Ewing, and C. W. Burger. "Stage III and IV endometrial cancer: a 20-year review of patients." International Journal of Gynecologic Cancer 16, no. 4 (2006): 1648–55. http://dx.doi.org/10.1136/ijgc-00009577-200607000-00024.

Full text

Abstract:

In advanced endometrial cancer, the importance of peritoneal cytology and optimal surgical cytoreduction remain subjects of discussion. We evaluated our clinical experience of 67 patients with FIGO stage III and IV endometrial cancer treated in the Erasmus Medical Centre in Rotterdam over a 20-year period with an emphasis on stage IIIA disease based on positive cytology only and optimal cytoreduction. Lymphadenectomy was not routinely performed and peritoneal cytology was examined in 74% of the patients. Stage IIIA disease was found in 33 patients, 10 of whom had positive cytology only. Analys

APA, Harvard, Vancouver, ISO, and other styles

31

Koirala, Pratistha, Ashley S. Moon, and Linus Chuang. "Clinical Utility of Preoperative Assessment in Ovarian Cancer Cytoreduction." Diagnostics 10, no. 8 (2020): 568. http://dx.doi.org/10.3390/diagnostics10080568.

Full text

Abstract:

Ovarian cancer is the deadliest gynecologic cancer, in part due to late presentation. Many women have vague early symptoms and present with disseminated disease. Cytoreductive surgery can be extensive, involving multiple organ systems. Novel therapies and recent clinical trials have provided evidence that, compared to primary cytoreduction, neoadjuvant chemotherapy has equivalent survival outcomes with less morbidity. There is increasing need for validated tools and mechanisms for clinicians to determine the optimal management of ovarian cancer patients.

APA, Harvard, Vancouver, ISO, and other styles

32

Sibirskaya, E. V., P. O. Nikiforova, and N. R. Rabadanova. "Primary cytoreductive surgery followed by chemotherapy compared to neoadjuvant chemotherapy followed by cytoreduction as a treatment for stage III and IV ovarian cancer (literature review)." Tumors of female reproductive system 20, no. 1 (2024): 124–30. http://dx.doi.org/10.17650/1994-4098-2024-20-1-124-130.

Full text

Abstract:

Standard treatment for advanced ovarian cancer (OC) consists of a combination of chemotherapy and cytoreductive surgery, but practice varies depending on the order of these 2 procedures: neoadjuvant chemotherapy followed by interval debulking surgery or primary cytoreduction followed by adjuvant chemotherapy. The aim of the work is to evaluate methods of treatment of OC of stages III, IV according to FIGO.The literature review includes publications in English from the PubMed, CochraneLibrary and Google Scholar databases on the use of neoadjuvant therapy and primary cytoreduction in late stages

APA, Harvard, Vancouver, ISO, and other styles

33

Yakovleva, M. G., T. V. Gorodnova, Kh B. Kotiv, et al. "Predicting the outcome of cytoreductive surgery in patients with advanced ovarian cancer." Tumors of female reproductive system 19, no. 1 (2023): 99–111. http://dx.doi.org/10.17650/1994-4098-2023-19-1-99-111.

Full text

Abstract:

Background. More than 80 % of cases ovarian cancer are detected at stage III–IV. One of the most important predictive factors is the cytoreductive surgery without residual tumor. Aim. To determine the selection criteria for cytoreductive surgery in the advanced ovarian cancer patients. Materials and methods. The study included 190 primary IIB–IV stage ovarian cancer patients who underwent surgical treatment in the oncogynecological department of the N. N. Petrov NMRC on Oncology in the period from August 2017 to August 2020. All patients underwent pelvic magnetic resonance imaging, chest and a

APA, Harvard, Vancouver, ISO, and other styles

34

Baruah, Upasana, Partha Sarathi Roy, and Debabrata Barmon. "Intraoperative Normothermic Intraperitoneal Chemotherapy Following Optimal Cytoreduction in Advanced Ca Ovary: A Feasibility Study." Asian Pacific Journal of Cancer Care 9, no. 2 (2024): 227–32. http://dx.doi.org/10.31557/apjcc.2024.9.2.227-232.

Full text

Abstract:

Introduction: Extrapolating the results from the studies using HIPEC, EPIC and normothermic intraperitoneal chemotherapy, we proposed that normothermic chemotherapy instilled after optimal cytoreduction will improve survival in patients who underwent optimal cytoreduction. We undertook this feasibility study with the aim of studying the effectiveness of intraoperative normothermic intraperitoneal chemotherapy in patients with advanced-stage epithelial carcinoma ovary. Methods: This was a single institutional feasibility study. The primary objective was progression-free survival (PFS) following

APA, Harvard, Vancouver, ISO, and other styles

35

Winarno, Gatot Nyarumenteng Adhipurnawan, Yudi Mulyana Hidayat, Setiawan Soetopo, Sofie Rifayani Krisnadi, Maringan Diapari Lumban Tobing, and Syahrul Rauf. "The Ability Pre-operative Serum (Cancer Antigen-125, Fatty Acid Synthase, and Glucose Transporter) to Predict Primary Suboptimal Cytoreduction in Epithelial Ovarian Cancer." Open Access Macedonian Journal of Medical Sciences 8, A (2020): 858–65. http://dx.doi.org/10.3889/oamjms.2020.4817.

Full text

Abstract:

BACKGROUND: The incidence of ovarian cancer ranks 8th in the world, with 295,414 cases and 184,799 death in 2018. Management in ovarian cancer is surgery and chemotherapy. Some studies state that patients who underwent optimal cytoreduction surgery have better survival rates than suboptimal cytoreduction surgery. The pre-operative serum assessed in this study was Cancer Antigen-125 (CA-125), Fatty Acid Synthase (FASN), and Glucose Transporter (GLUT) to predict suboptimal cytoreduction in epithelial ovarian cancer (EOC). AIM: We aimed to use FASN and GLUT1 as other biomarkers, besides CA-

APA, Harvard, Vancouver, ISO, and other styles

36

Nelson, B. E., A. T. Rosenfield, and P. E. Schwartz. "Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma." Journal of Clinical Oncology 11, no. 1 (1993): 166–72. http://dx.doi.org/10.1200/jco.1993.11.1.166.

Full text

Abstract:

PURPOSE This study was undertaken to assess the ability of computed tomography (CT) to predict the likelihood of optimal primary tumor cytoreduction in women with epithelial ovarian carcinoma. PATIENTS AND METHODS Fifty-one women with preoperative CT and a histologic diagnosis of epithelial ovarian carcinoma following primary tumor operation by a gynecologic oncologist were identified. Forty-two CT scans were retrospectively analyzed. CT findings of attachment of the omentum to the spleen or disease greater than 2 cm on the diaphragm, liver surface, or parenchyma, pleura, mesentery, gallbladde

APA, Harvard, Vancouver, ISO, and other styles

37

Vasquez, Flavia Morales, Ricardo Raziel Peña Gonzalez, and Horacio Noé López Basave. "Predictive factors of cytoreductive surgery in epithelial ovarian cancer in a Mexican women cohort." Journal of Clinical Oncology 37, no. 15_suppl (2019): e17099-e17099. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e17099.

Full text

Abstract:

e17099 Background: Cytoreductive surgery is the most important prognostic factor in ovarian cancer. To identify in a timely manner the patients who are not candidates for optimal debulking, does not delay and optimize the treatment. Objetive: Identify the presurgical factors that characterize patients in whom optimal cytoreduction is not possible. Methods: Observational study in a retrospective cohort (n = 255) that compared pre-surgical factors between patients with optimal debulking (n = 65) and suboptimal (n = 190). Non-parametric tests were used, a Cox proportional hazards model was constr

APA, Harvard, Vancouver, ISO, and other styles

38

Kim, Rachel Soyoun, Janet Malcolmson, Xuan Li, Marcus Bernardini, Liat Frida Hogen, and Taymaa May. "The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma." Journal of Clinical Oncology 39, no. 15_suppl (2021): 5543. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.5543.

Full text

Abstract:

5543 Background: High grade serous ovarian cancers (HGSC) with BRCA mutation are biologically unique, with distinct molecular and clinical behaviour from sporadic cases. It is unclear if these biological differences translate to favorable outcomes at the time of primary cytoreductive surgery (PCS). The aim of this study is to compare the amount of residual disease following PCS in BRCA-mutated (BRCAm) and wildtype (BRCAwt) HGSC, and to assess whether BRCA status is an independent predictor of residual disease. Methods: We conducted a retrospective analysis of patients with HGSC with known germ

APA, Harvard, Vancouver, ISO, and other styles

39

Lorusso, D., M. Mancini, R. Di Rocco, R. Fontanelli, and F. Raspagliesi. "The Role of Secondary Surgery in Recurrent Ovarian Cancer." International Journal of Surgical Oncology 2012 (2012): 1–6. http://dx.doi.org/10.1155/2012/613980.

Full text

Abstract:

Despite optimal treatment (complete cytoreduction and adjuvant chemotherapy), 5-year survival for advanced ovarian cancer is approximately 30% and most patients succumb to their disease. Cytoreductive surgery is accepted as a major treatment of primary ovarian cancer but its role in recurrent disease is controversial and remains a field of discussion mainly owing to missing data from prospective randomized trials. A critical review of literature evidence on secondary surgery in recurrent ovarian cancer will be described.

APA, Harvard, Vancouver, ISO, and other styles

40

Fader, Amanda Nickles, and Peter G. Rose. "Role of Surgery in Ovarian Carcinoma." Journal of Clinical Oncology 25, no. 20 (2007): 2873–83. http://dx.doi.org/10.1200/jco.2007.11.0932.

Full text

Abstract:

Surgery plays a critical role in the optimal management of all stages of ovarian carcinoma. In apparent early-stage ovarian cancer, a comprehensive surgical evaluation allows stratification of patients into low- and high-risk categories. Low-risk patients may be candidates for fertility-sparing surgery and can safely avoid chemotherapy and be observed. Treatment of patients with high-risk early- or advanced-stage ovarian cancer usually requires a combined modality approach. Although it is well known that epithelial ovarian cancer is moderately chemosensitive, what distinguishes it most from ot

APA, Harvard, Vancouver, ISO, and other styles

41

Shrestha Prajapati, Shristee, Anisha Shrestha, Usha Bade Shrestha, et al. "Primary Cytoreductive Surgery versus Neoadjuvant Chemotherapy followed by Interval Cytoreductive Surgery for Advanced Epithelial Ovarian Cancer: A Retrospective Cohort Study." Nepalese Journal of Cancer 7, no. 1 (2023): 33–39. http://dx.doi.org/10.3126/njc.v7i1.60019.

Full text

Abstract:

Introduction: Epithelial ovarian cancer (EOC) represents about two-thirds of ovarian malignancies and usually presents with advanced disease. Primary cytoreductive (PCR) surgery is known to be the cornerstone of treatment of advanced EOC, but it might not always be feasible to obtain optimal cytoreduction. Neoadjuvant chemotherapy (NACT) has been proposed as an alternative approach. This study aims to compare the survival of patients, post-operative morbidity and the extent of cytoreduction that was achieved among the two treatment groups. Methods: A retrospective cohort study was done in Bhak

APA, Harvard, Vancouver, ISO, and other styles

42

V., S. Svintsitskiy, P. Tsip N., V. Nespryadko S., et al. "LYMPH NODES DISSECTION IN ADVANCED OVARIAN CANCER." REPRODUCTIVE ENDOCRINOLOGY, no. 55 (November 30, 2020): 90–93. https://doi.org/10.18370/2309-4117.2020.55.90-93.

Full text

Abstract:

Ovarian cancer becomes the most aggressive disease among all cancer pathology in women’s reproductive system. Surgery and chemotherapy are the main options on the way of ovarian cancer treatment. Cytoreductive surgeries are the main way of surgical treatment of patients with advanced ovarian cancer. The goal of this kind of surgeries is resections of all macroscopic implants. The opportunity of systematic lymph nodes dissection from renal vessels to obturator nerve is the reason of scientific discussion. LION trial (Lymphadenectomy In Ovarian Neoplasms) showed no significant difference i

APA, Harvard, Vancouver, ISO, and other styles

43

Risum, Signe, Estrid Høgdall, Svend A. Engelholm, et al. "A Proteomics Panel for Predicting Optimal Primary Cytoreduction in Stage III/IV Ovarian Cancer." International Journal of Gynecologic Cancer 19, no. 9 (2009): 1535–38. http://dx.doi.org/10.1111/igc.0b013e3181a840f5.

Full text

Abstract:

The objective of this prospective study was to evaluate CA-125 and a 7-marker panel as predictors of incomplete primary cytoreduction in patients with stage III/IV ovarian cancer (OC). From September 2004 to January 2008, serum from 201 patients referred to surgery for a pelvic tumor was analyzed for CA-125. In addition, serum was analyzed for 7 biomarkers using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. These biomarkers were combined into a single-valued ovarian-cancer-risk index (OvaRI). CA-125 and OvaRI were evaluated as predictors of cytoreduction in 75

APA, Harvard, Vancouver, ISO, and other styles

44

Pomel, Christophe, Cherrif Akladios, Eric Lambaudie, et al. "Laparoscopic management of advanced epithelial ovarian cancer after neoadjuvant chemotherapy: a phase II prospective multicenter non-randomized trial (the CILOVE study)." International Journal of Gynecologic Cancer 31, no. 12 (2021): 1572–78. http://dx.doi.org/10.1136/ijgc-2021-002888.

Full text

Abstract:

ObjectiveThe aim of this study was to explore the feasibility and safety of the laparoscopic approach after neoadjuvant chemotherapy among selected chemosensitive patients with advanced ovarian cancer.MethodsThe CILOVE study was a phase II prospective non-randomized multicenter study. It aimed to enroll 47 women with unresectable disease at the time of initial diagnosis (International Federation of Gynecology and Obstetrics (FIGO) stage IV and/or diffuse extensive carcinomatosis for advanced FIGO stage IIIC or patients unfit to withstand radical primary surgery), in response to chemotherapy an

APA, Harvard, Vancouver, ISO, and other styles

45

Lekawale, Hemant S., and Rachana V. Gaidole. "Outcomes of surgery in epithelial ovarian cancer: our experience." International Surgery Journal 6, no. 11 (2019): 3906. http://dx.doi.org/10.18203/2349-2902.isj20194576.

Full text

Abstract:

Background: Comprehensive surgical staging and surgical cytoreduction is the primary modality of treatment in early and advanced epithelial ovarian cancer respectively, followed by systemic chemotherapy in most of the patients. The aim of the present study was to evaluate the role of surgery and its impact on disease free and overall survival in patients with epithelial ovarian cancer.Methods: A retrospective analysis of 38 patients of biopsy proven epithelial ovarian cancer was performed. Patient’s demographic data, details of surgical procedure, post-operative complications, histopathologica

APA, Harvard, Vancouver, ISO, and other styles

46

de Jong, D., J. E. Dodge, O. Freedman, E. Lo, B. P. Rosen, and H. Mackay. "Predictors for optimal cytoreduction following neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma." Journal of Clinical Oncology 27, no. 15_suppl (2009): 5512. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.5512.

Full text

Abstract:

5512 Background: Neoadjuvant chemotherapy (NAC) is increasingly used to treat patients (pts) with presumed advanced-stage epithelial ovarian cancer (EOC) who are deemed ineligible for upfront debulking surgery (DS). DS following NAC offers a survival benefit to those pts in whom optimal cytoreduction (< 1 cm residual tumor) is achieved. However, not all women who commence NAC have a subsequent attempt at DS. The aims of this study were to identify, in pts planned for NAC, predictive parameters for attempting DS and for achieving optimal cytoreduction in those undergoing surgery. Methods: Pt

APA, Harvard, Vancouver, ISO, and other styles

47

Dhiman, Pravesh, P. P. Bapsy, C. N. Patil, and Renu Raghupathi. "Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?" South Asian Journal of Cancer 11, no. 03 (2022): 207–12. http://dx.doi.org/10.1055/s-0042-1755291.

Full text

Abstract:

Background Epithelial ovarian cancer (EOC) is one of the leading causes of cancer-related death in women. Approximately 70% of patients with EOC are diagnosed in advanced stage [The International Federation of Gynecology and Obstetrics(FIGO stage III and IV)] with an expected 5-year survival rate of 30%. Numerous studies have shown that survival with neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is noninferior to primary debulking surgery followed by chemotherapy. Materials and Methods In this retroprospective observational study, 50 patients with advanced ovaria

APA, Harvard, Vancouver, ISO, and other styles

48

Ceccaroni, Marcello, Giovanni Roviglione, Francesco Bruni, et al. "“Things Have Changed”—Laparoscopic Cytoreduction for Advanced and Recurrent Ovarian Cancer: The Experience of a Referral Center on 108 Patients." Cancers 15, no. 24 (2023): 5726. http://dx.doi.org/10.3390/cancers15245726.

Full text

Abstract:

Objective: To report the feasibility of laparoscopic cytoreduction surgery for primary and recurrent ovarian cancer in a select group of patients. Methods: A retrospective analysis was conducted on a cohort of patients with FIGO stage IIIA-IV advanced ovarian cancer who underwent laparoscopic primary debulking surgery (PDS), interval debulking surgery (IDS), or secondary debulking surgery (SDS) between June 2008 and January 2020. The primary endpoint was achieving optimal cytoreduction, defined as residual tumor less than 1 cm. Secondary endpoints included evaluating surgical complications and

APA, Harvard, Vancouver, ISO, and other styles

49

Di Donna, Mariano Catello, Giuseppe Cucinella, Giulia Zaccaria, et al. "Concordance of Radiological, Laparoscopic and Laparotomic Scoring to Predict Complete Cytoreduction in Women with Advanced Ovarian Cancer." Cancers 15, no. 2 (2023): 500. http://dx.doi.org/10.3390/cancers15020500.

Full text

Abstract:

Objective: To identify the best method among the radiologic, laparoscopic and laparotomic scoring assessment to predict the outcomes of cytoreductive surgery in patients with advanced ovarian cancer (AOC). Methods: Patients with AOC who underwent pre-operative computed tomography (CT) scan, laparoscopic evaluation, and cytoreductive surgery between August 2016 and February 2021 were retrospectively reviewed. Predictive Index (PI) score and Peritoneal Cancer Index (PCI) scores were used to estimate the tumor load and predict the residual disease in the primary debulking surgery (PDS) and interv

APA, Harvard, Vancouver, ISO, and other styles

50

Griffiths, C. T., L. M. Parker, S. Lee, and N. J. FINKLER. "The effect of residual mass size on response to chemotherapy after surgical cytoreduction for advanced ovarian cancer: Long-term results." International Journal of Gynecologic Cancer 12, no. 4 (2002): 323–31. http://dx.doi.org/10.1136/ijgc-00009577-200207000-00001.

Full text

Abstract:

We report an observational study of chemotherapeutic regression of ovarian tumor implants according to decrements in residual mass size after surgical cytoreduction. Cytoreductive operations were attempted on 74 consecutive patients with stages IIIB-IV disease referred for this purpose. Thirty-two patients had received one to four courses of preoperative chemotherapy (22 responses, no progressions). Postoperative chemotherapy followed current protocols at Dana Farber Cancer Institute (n=61) or referring institutions (n=13); 57 regimens contained cisplatin. Postchemotherapy response was assesse

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!